Jeffrey Thomas
Medical · North Little Rock, ARNPI 1013281609
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,384 of the $5,888 with a category attached, or 74.5%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.4%. Reporting peaked in 2021 at $1,964 and has fallen 57.5% since, to $835 in 2025.
Across 231 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$1K
- Sumitomo Pharma America, Inc.$612
- Johnson & Johnson$554
- Astellas Pharma US Inc$538
- Dendreon Pharmaceuticals LLC$457
- Novartis$456
- plus $2K from 22 others
What the payments were for
- Consulting fees$1,21521%
- Food & beverage$4,38474%
- Education$2895%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 4 | $1,258 |
| Sumitomo Pharma America, Inc. | 36 | $612 |
| Johnson & Johnson | 31 | $554 |
| Astellas Pharma US Inc | 18 | $538 |
| Dendreon Pharmaceuticals LLC | 19 | $457 |
| Novartis | 23 | $456 |
| Myriad Genetic Laboratories, Inc. | 12 | $376 |
| AbbVie | 13 | $232 |
| Blue Earth Diagnostics | 12 | $220 |
| Myovant Sciences Inc. | 10 | $167 |
| Pfizer | 9 | $164 |
| Antares Pharma, Inc. | 6 | $121 |
| Bayer | 6 | $104 |
| Urogen Pharma, Inc. | 6 | $98 |
| Amgen | 4 | $84 |
| Urovant Sciences Inc | 4 | $76 |
| Merck | 3 | $59 |
| Photocure Inc | 2 | $54 |
| Teleflex LLC | 2 | $47 |
| Rochester Medical Corporation | 2 | $40 |
| Procept Biorobotics Corporation | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 2 | $28 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Sanofi | 1 | $22 |
| Boston Scientific | 1 | $16 |
| Tolmar, Inc. | 1 | $14 |
| Axonics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,888 in reported general payments places this provider in the 85th percentile of 133 medical providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $286,989 |
| MyrbetriqMirabegron | 49 | $33,064 |
| GemtesaVibegron | 36 | $25,413 |
| Tamsulosin Hcl | 590 | $9,646 |
| Solifenacin Succinate | 128 | $4,767 |
| Finasteride | 287 | $3,386 |
| Silodosin | 49 | $2,926 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 26 | $2,833 |
| Testosterone Cypionate | 47 | $2,041 |
| Dutasteride | 54 | $1,582 |
| Oxybutynin Chloride ErOxybutynin Chloride | 115 | $1,471 |
| Megestrol Acetate | 62 | $1,060 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $889 |
| Potassium Citrate ErPotassium Citrate | 11 | $693 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $538 | $320,05370 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $612 | $25,41336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 133 medical providers in Arkansas.
Other medical in North Little Rock
- Joshua JohnsonNorth Little Rock$6K
- Matthew ReynoldsRussellville$207K
- Tara BrunerSearcy$16K
- Dallas BondhusHot Springs$15K
- Douglas ClarkLittle Rock$14K
- Alexandra SanromaLittle Rock$11K
- Caleb MasonSearcy$9K
- Katherine McCradyLittle Rock$9K
- Bailey PollockLittle Rock$9K
- Hannah BreauLittle Rock$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.